| Trial ID: | L2709 |
| Source ID: | NCT01722240
|
| Associated Drug: |
Liraglutide 1.8mg
|
| Title: |
Liraglutide in Type 1 Diabetes
|
| Acronym: |
1966
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01722240/results
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: Liraglutide 1.8mg|DRUG: Placebo
|
| Outcome Measures: |
Primary: HbA1c (%), HbA1c measured at baseline and after 52 weeks of treatment with Liraglutide or placebo., 52 Weeks | Secondary: Mean Weekly Glucose Concentrations., Mean weekly glucose concentrations measured by CGM at baseline and at 52 weeks, 52 Weeks|Body Weight, Body weight in Kg measured at weeks 0 (baseline) and at 52 weeks after treatment with liraglutide or placebo, 52 weeks
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
69
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-11-01
|
| Completion Date: |
2019-07-29
|
| Results First Posted: |
2024-01-23
|
| Last Update Posted: |
2024-01-23
|
| Locations: |
Diabetes-Endocrinology Center of WNY, Buffalo, New York, 14215, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01722240
|
